Close Menu

NEW YORK (GenomeWeb) – Transgenomic today announced that it has non-exclusively licensed its portfolio of intellectual property related to DNA susceptibility testing for long QT syndrome to Laboratory Corporation of America.

Long QT syndrome is a primarily congenital heart rhythm disorder associated with cardiac arrhythmia and can be triggered by prescription medicines in individuals prone to the condition.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
10

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.